Capricor Therapeutics (CAPR) stock is in focus after the company presented Phase 3 HOPE 3 data for Deramiocel in Duchenne muscular dystrophy at the American Academy of Neurology 2026 Annual Meeting.

That update comes after a sharp move in Capricor Therapeutics stock, with a 1-day share price return of 8.38% and a 90-day share price return of 34.65%, alongside a very large 1-year total shareholder return that sits in the mid single digit multiple of the original investment. This points to strong momentum around Deramiocel's progress.

If this kind of biotech catalyst has your attention, it could be a useful moment to see what else is setting up for potential breakthroughs across 33 healthcare AI stocks

With Capricor Therapeutics now carrying a market value near US$1.8b and a recent close of US$33.50, plus a large implied gap to analyst targets and intrinsic estimates, is there still mispricing here or has the market already priced in future growth?

Most Popular Narrative: 38.7% Undervalued

Capricor Therapeutics' most followed narrative pegs fair value at $54.67 against the last close of $33.50, framing a wide gap investors are watching closely.

The analysts have a consensus price target of $54.67 for Capricor Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $63.0, and the most bearish reporting a price target of just $43.0.

Want to see what is driving that fair value gap? The narrative focuses on rapid revenue expansion, sharp margin improvement and a rich future earnings multiple. The full breakdown shows how those moving parts fit together into a single valuation story.

Result: Fair Value of $54.67 (UNDERVALUED)

However, the story can change quickly if Deramiocel faces further FDA setbacks or if Capricor needs extra capital to fund rising R&D and operating costs.

Next Steps

With sentiment clearly split between risks and rewards, this is the kind of setup where you may want to check the numbers yourself and move quickly to shape your own view by weighing up the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Capricor Therapeutics is on your radar, do not stop here. Broader opportunities across different styles, sectors, and risk levels could sharpen your next move.

• Target potential value opportunities by scanning 48 high quality undervalued stocks that match strong fundamentals with what may be attractive pricing.
• Prioritise resilience by focusing on companies in the 70 resilient stocks with low risk scores that carry lower risk scores while still offering meaningful exposure to equities.
• Hunt for tomorrow's standouts early using the screener containing 25 high quality undiscovered gems, where underfollowed stocks with solid foundations are waiting for fresh attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.